Binding Database

19 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

Exelixis

22765894

223

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

Exelixis

23127890

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

Exelixis

22497444

Discovery and characterization of an inhibitor of glucosylceramide synthase.

Exelixis

22548342

210

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors.

Exelixis

22542012

155

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Exelixis

22560567

Discovery of XL413, a potent and selective CDC7 inhibitor.

Exelixis

22450127

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.

Exelixis

22214363

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.

Exelixis

22342124

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Exelixis

21974949

Discovery of a new class of glucosylceramide synthase inhibitors.

Exelixis

22877636

Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.

Exelixis

19159286

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR).

Exelixis